Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My point exactly to skully that bmsn IS NOT on the big boards so LEE JACKSON would not pick it up only till we get there Skully was inclined to question why wasn't bmsn on his list.
Lee Jackson has never recommended a sub penny until BMSN is 0n a big board only then will the Street take interest.
“2013 was most noteworthy in that we saw the solidification of our Certified Liquidmetal Partners program and the commercial availability of a standard injection molding machine from Engel and both beryllium and non-beryllium alloys from Materion,” said Tom Steipp, President and CEO. “These events set the stage for our attracting a top industry sales and support executive in Paul Hauck, who will now lead the sales and marketing activities as we push beyond the prototype phases into full production of customer parts.”
Can't wait to see what he's accomplished so far for lqmt
http://www.linkedin.com/pub/paul-hauck/14/362/259
Today up 19% Past few days Average Volume has been building
Aug 7, 2014 0.01 0.01 0.01 0.01 173,300 0.01
Aug 6, 2014 0.01 0.01 0.01 0.01 376,000 0.01
Aug 5, 2014 0.02 0.02 0.01 0.01 2,822,700 0.01
Aug 4, 2014 0.01 0.02 0.01 0.02 908,300 0.02
Aug 1, 2014 0.01 0.01 0.01 0.01 36,400 0.01
Average monthly Price action and volume
Aug 1, 2014 0.01 0.02 0.01 0.01 898,000 0.01
Jul 1, 2014 0.02 0.03 0.01 0.01 534,300 0.01
Jun 2, 2014 0.01 0.03 0.01 0.02 591,400 0.02
May 1, 2014 0.02 0.02 0.01 0.01 324,800 0.01
Apr 1, 2014 0.02 0.03 0.02 0.02 604,900 0.02
Mar 3, 2014 0.04 0.05 0.02 0.02 1,190,700 0.02
Feb 3, 2014 0.02 0.07 0.01 0.04 1,561,600 0.04
bullish flag confirmed
May 20, 2014 – XsunX, Inc. (OTCQB: XSNX)
With the sales through project delivery cycle requiring about 3 to 6 months for commercial systems, we are pleased to see that our early efforts are now resulting in so much positive momentum.”
We're today Nearing 3mths timeline.
Anyone noticed the website XSNX hiring Business must be great!!!!!
http://www.xsunx.com/
News should be breaking soon (IMO)
I'm all out I'll stay on the side lines I'll keep SLTD on my watch list I"LL BE BACK GO SLTD
Depending on how you look at the glass half full or half empty BMSN has made great stride in the field of developing a cure for cancer. How much has it cost BMSN... compare that... to what has been spent to get where BMSN is ....by the other research labs and NO ONE HAS THE SUCCESSFULLY ACHIEVED THIS STAGE ... SAN DIEGO, CA--(Marketwired - Aug 1, 2014) - Regen BioPharma Inc. (a company majority owned by Bio-Matrix Scientific Group Inc.) (PINKSHEETS: BMSN) reported today on progress in development of dCellVax, a "therapeutic cancer vaccine" which stimulates the immune system of patients to selectively kill tumors.
Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma, stated, "We are pleased to announce that Regen BioPharma has successfully achieved silencing of the IDO gene in human dendritic cells, which is a major step forward in development of our Investigational New Drug (IND) application to the FDA." He further noted that "Not only is this a significant milestone, but this provides additional trade secrets in our production methodology with the possibility of filing new patents on the optimized methodology and reagents we have developed."
Pete I Suggest you get educated in the field of Technical Analysis
You Can Begin you DD http://www.mta.org/eweb/dynamicpage.aspx?webcode=what-is-technical-analysis
gap filled .0027 get ready
50 day has to tested .15 if double bottom forms on it we're taking off if not we'll come back to the 200 (IMO)
Profit taking and falling hard 200 day showing .09
http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm
"The role of the FDA is to ensure the highest standards of safety for new products. We view the requested clarifications from the FDA in regards to safety studies as part of the normal process of FDA submission. Given that the HemaXellerate I™ possesses the potential to treat multiple conditions, we view the demonstration of safety as a fundamental step, which will position the Company to expand use of this 'stem cell drug' for multiple other indications," noted David Koos, the Company's Chairman & CEO. "Having passed the clinical trial protocol approval and the manufacturing approval, are major milestones for Regen."
On May 9, 2014 the Company updated its IND with changes requested by the FDA and submitted them for review.
two birds with one stone
KNOW WHAT YOU INVEST IN BMSN
Great Job Done so far David Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
Senior Vice President of Research and Development at Tacere Therapeutics (a Subsidiary of Benitec Biopharma) to Help Guide Regen's Cancer Immunotherapy Program
BMSN Dcell vax works !!
BMSN have found the answer
We're leaving the gate ladies and gentlemen
it looks like we're about to lift off check your seat belt and put your chairs in an upright position ladies and gentlemen.
BMSN Have the final piece to the puzzle could be a bidding war soon for it's technology
Intrexon Corporation CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints, yet current approaches feature challenges associated with toxicity, off-target effects, and uneconomical manufacturing.
Intrexon possesses the integrated technology platforms, molecular engineering, systems biology, and cell engineering capabilities required to overcome these challenges and fully realize the potential of CAR-T cell therapies.
New financing options have resulted in accelerating the pace of sales and the number of solar system proposals in the company's sales pipeline.
"The level of interest we are seeing in commercial solar systems is quite extraordinary," stated XsunX CEO, Tom Djokovich. "In June alone we added over 1-megawatt of commercial solar system proposals to our sales pipeline totaling over $3 million, and that's just the beginning of what we see as increasing business opportunities through the expansion of our commercial systems sales force."
Any guesses as to amount of sales thus far?
D Cell Vax is vastly superior Quark's RNAi treatment misses the mark in a Phase II kidney trial
July 29, 2014 | By Damian Garde
Share
Tools
Comment
Print
Contact Author
Reprint
Quark Pharmaceuticals' gene-silencing treatment for kidney transplant complications missed its primary endpoint in a Phase II trial, possibly jeopardizing a deal with Novartis ($NVS) worth up to $680 million.
The treatment, QPI-1002, is a small interfering RNA (siRNA) designed to shut off the p53 gene in kidney transplant patients, thereby protecting tissues from damage caused by a disorder called delayed graft function. Quark mounted a 331-patient Phase II trial in hopes the treatment could meet its primary endpoint of a 30% relative risk reduction compared to placebo, but QPI-1002 came through at just 15.1%, missing its main goal.
Quark was quick to point out that its drug crossed the 30% threshold in a few patient subgroups, and the biotech noted that safety signals were similar between the trial's treatment and placebo arms. QPI-1002's benefits were particularly pronounced in patients whose kidney donors were older than 45, Quark said, and the company believes the results merit further study.
IBM SmarterCommerce Webinar: File Synch / File Share for the Enterprise – Taken to the Extreme
Join this webinar with Derek Brink, Vice President and Research Fellow for IT Security and IT GRC at the Aberdeen Group, to discover how to develop your own innovative approach to managed file transfer. Find out how to bring new levels of efficiency, visibility and collaboration to every process – and reach new heights of success for your business. Click here to watch this on-demand webinar today! .
Sign up for our FREE newsletter for more news like this sent to your inbox!
But whether there's a Phase III effort in store remains up in the air.
Back in 2010, Novartis stepped in and paid $10 million up front for an option to license QPI-1002, promising to hand over up to $670 million more in fees and milestones if the gene-silencing treatment met its standards for success. Flunking a primary endpoint in Phase II would seem like a deal-breaker, but Novartis hasn't provided an update on the outstanding deal and didn't respond to a request for comment on Tuesday.
Novartis has already curtailed much of its internal RNAi research efforts, telling FierceBiotech in April that that decision stemmed from "ongoing challenges with formulation and delivery and the reality that the current range of medically relevant targets where siRNA may be used is quite narrow."
As for Quark, while its upbeat announcement is littered with recommendations for additional studies of QPI-1002, the company has made no mention of a planned Phase III, and, like Novartis, it didn't respond to emailed questions on the matter.
Beyond QPI-1002, Quark's clinical siRNA pipeline includes the Pfizer ($PFE)-partnered PF-655, in midstage development for diabetic macular edema and wet age-related macular degeneration, and QPI-1007, a wholly owned treatment for optic neuropathy and glaucoma.
Breakthrough Therapy
Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).
To determine whether the improvement over available therapy is substantial is a matter of judgment and depends on both the magnitude of the drug's effect on a clinically significant endpoint (which could include duration of the effect) and the importance of the observed effect to the treatment of the serious condition or serious aspect of the condition. In general, the preliminary clinical evidence should show a clear advantage over available therapy.
For purposes of Breakthrough Therapy designation, clinically significant endpoint generally refers to an endpoint that measures an effect on irreversible morbidity or mortality (IMM) or on symptoms that represent serious consequences of the disease. A clinically significant endpoint can also refer to findings that suggest an effect on IMM or serious symptoms, including:
Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious conditions.
FDA will fast track this(IMO)
News From BMSN "We are pleased to announce that Regen BioPharma has successfully achieved silencing of the IDO gene in human dendritic cells, which is a major step forward in development of our Investigational New Drug (IND) application to the FDA.
These are the first experiments in which human cells were utilized in a manner similar to which will be filed with the FDA.
Cancer treatment is in the trillions globally
"Is Successful " "not "going to be" or "Might Be" dCellVax, a "therapeutic cancer vaccine" which stimulates the immune system of patients to selectively kill tumors.
Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma, stated, "We are pleased to announce that Regen BioPharma has successfully achieved silencing of the IDO gene in human dendritic cells
Wait until This hits the Big Boys this is the stuff dreams are made of Hold onto every share you got and Buy as much as you can if you've anyone who had to endure treatments of radiation then you know what this means
bmsn reported that it was likely to update in August and they did
Know What You Buy !!!! Regen BioPharma has successfully achieved silencing of the IDO gene in human dendritic cells,
Got Some More of BMSN today
Novartis and the rest BMSN has the success under it's belt how much will you pay?
D Cell Vax is vastly superior Quark's RNAi treatment misses the mark in a Phase II kidney trial
July 29, 2014 | By Damian Garde
Share
Tools
Comment
Print
Contact Author
Reprint
Quark Pharmaceuticals' gene-silencing treatment for kidney transplant complications missed its primary endpoint in a Phase II trial, possibly jeopardizing a deal with Novartis ($NVS) worth up to $680 million.
The treatment, QPI-1002, is a small interfering RNA (siRNA) designed to shut off the p53 gene in kidney transplant patients, thereby protecting tissues from damage caused by a disorder called delayed graft function. Quark mounted a 331-patient Phase II trial in hopes the treatment could meet its primary endpoint of a 30% relative risk reduction compared to placebo, but QPI-1002 came through at just 15.1%, missing its main goal.
Quark was quick to point out that its drug crossed the 30% threshold in a few patient subgroups, and the biotech noted that safety signals were similar between the trial's treatment and placebo arms. QPI-1002's benefits were particularly pronounced in patients whose kidney donors were older than 45, Quark said, and the company believes the results merit further study.
IBM SmarterCommerce Webinar: File Synch / File Share for the Enterprise – Taken to the Extreme
Join this webinar with Derek Brink, Vice President and Research Fellow for IT Security and IT GRC at the Aberdeen Group, to discover how to develop your own innovative approach to managed file transfer. Find out how to bring new levels of efficiency, visibility and collaboration to every process – and reach new heights of success for your business. Click here to watch this on-demand webinar today! .
Sign up for our FREE newsletter for more news like this sent to your inbox!
But whether there's a Phase III effort in store remains up in the air.
Back in 2010, Novartis stepped in and paid $10 million up front for an option to license QPI-1002, promising to hand over up to $670 million more in fees and milestones if the gene-silencing treatment met its standards for success. Flunking a primary endpoint in Phase II would seem like a deal-breaker, but Novartis hasn't provided an update on the outstanding deal and didn't respond to a request for comment on Tuesday.
Novartis has already curtailed much of its internal RNAi research efforts, telling FierceBiotech in April that that decision stemmed from "ongoing challenges with formulation and delivery and the reality that the current range of medically relevant targets where siRNA may be used is quite narrow."
As for Quark, while its upbeat announcement is littered with recommendations for additional studies of QPI-1002, the company has made no mention of a planned Phase III, and, like Novartis, it didn't respond to emailed questions on the matter.
Beyond QPI-1002, Quark's clinical siRNA pipeline includes the Pfizer ($PFE)-partnered PF-655, in midstage development for diabetic macular edema and wet age-related macular degeneration, and QPI-1007, a wholly owned treatment for optic neuropathy and glaucoma.
"Not only is this a significant milestone, but this provides additional trade secrets in our production methodology with the possibility of filing new patents on the optimized methodology and reagents we have developed."
$$$$$$$$Dcell vax successful$$$$$$$$$Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma, stated, "We are pleased to announce that Regen BioPharma has successfully achieved silencing of the IDO gene in human dendritic cells, which is a major step forward in development of our Investigational New Drug (IND) application to the FDA."